Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 503

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 503
---
 failed to complete our initial business combination by December 6, 2024, Nasdaq’s staff concluded that APx did not comply with Rule IM -5101-2and that APx’s securities are now subject to delisting. As a result, trading in APx’s securities on Nasdaq was effectively suspended with the open of the market on December 17, 2024, and APx’s securities are currently eligible to trade only on the over -the -countermarkets system. On March 21, 2025, Nasdaq filed a Form 25 -NSEin respect of APx’s Class A ordinary shares with the SEC, and the delisting of APx’s Class A ordinary shares became effective on March 31, 2025. On May 8, 2025, Nasdaq filed a Form 25 -NSEin respect of APx’s units and warrants with the SEC, and the delisting of APx’s units and warrants will become effective on May 18, 2025. Following the delisting on Nasdaq, APx’s Class A ordinary shares are quoted on the Pink Open Market of the OTC under the symbol “APXIF”. We will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information. Despite the delisting of our securities from Nasdaq, the Company intends to proceed with its efforts to consummate our initial Business Combination. However, Nasdaq approval of OmnigenicsAI’s initial listing application with respect to the Business Combination is a condition to such Business Combination, and there can be no guarantee that Nasdaq will approve such initial listing application, which may delay, or ultimately prevent the consummation of the proposed Business Combination. Following the suspension of trading on Nasdaq, the Company’s Class A ordinary shares are quoted on the Pink Open Market of the OTC under the symbol “APXIF”. The Company will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information. First, Second and Third Extensions On February 27, 2023, the Company held an extraordinary general meeting (the “February 2023 EGM”) and its shareholders approved an amendment to its amended and restated memorandum and articles of association (as amended, the “Articles of Association”) and to the investment management trust agreement dated as of September 7, 2021 (as amended, the “Trust Agreement”)